CN102985425A - 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 - Google Patents
作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 Download PDFInfo
- Publication number
- CN102985425A CN102985425A CN2011800339890A CN201180033989A CN102985425A CN 102985425 A CN102985425 A CN 102985425A CN 2011800339890 A CN2011800339890 A CN 2011800339890A CN 201180033989 A CN201180033989 A CN 201180033989A CN 102985425 A CN102985425 A CN 102985425A
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- pyrrolo
- nonane
- diaza spiro
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 ***(CN(*)CC1(CC1)C1)CN1c1nc(*)nc2c1cc[n]2 Chemical compound ***(CN(*)CC1(CC1)C1)CN1c1nc(*)nc2c1cc[n]2 0.000 description 5
- WTWAGYVXUUZNQF-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN(Cc2ccccc2)C1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN(Cc2ccccc2)C1=O)=O WTWAGYVXUUZNQF-UHFFFAOYSA-N 0.000 description 1
- ZXAZMIHBIYKDTN-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(Cc2ccccc2)C2(CC2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(Cc2ccccc2)C2(CC2)CC1)=O ZXAZMIHBIYKDTN-UHFFFAOYSA-N 0.000 description 1
- WURLLWFTFBYDFN-UHFFFAOYSA-N Nc1nc(N2CC3(CC3)CN(Cc3ccccc3)CC2)c(cc[nH]2)c2n1 Chemical compound Nc1nc(N2CC3(CC3)CN(Cc3ccccc3)CC2)c(cc[nH]2)c2n1 WURLLWFTFBYDFN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36309510P | 2010-07-09 | 2010-07-09 | |
US61/363,095 | 2010-07-09 | ||
PCT/DK2011/000080 WO2012003829A1 (fr) | 2010-07-09 | 2011-07-08 | Nouveaux dérivés d'homopipérazine comme inhibiteurs de protéines tyrosine kinases et leur utilisation pharmaceutique |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102985425A true CN102985425A (zh) | 2013-03-20 |
Family
ID=44513700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800339890A Pending CN102985425A (zh) | 2010-07-09 | 2011-07-08 | 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9586961B2 (fr) |
EP (1) | EP2590981B1 (fr) |
JP (1) | JP2013533868A (fr) |
CN (1) | CN102985425A (fr) |
RU (1) | RU2013105450A (fr) |
TW (1) | TW201204732A (fr) |
WO (1) | WO2012003829A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103242321A (zh) * | 2013-05-21 | 2013-08-14 | 苏州科捷生物医药有限公司 | 苄基哌嗪类化合物及其抗肿瘤用途 |
CN103396414A (zh) * | 2013-07-16 | 2013-11-20 | 浙江医药高等专科学校 | 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
CN104072499A (zh) * | 2013-03-29 | 2014-10-01 | 黄传满 | 哌嗪取代嘧啶类化合物及其用途 |
CN105712998A (zh) * | 2014-12-05 | 2016-06-29 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
CN106061973A (zh) * | 2013-12-05 | 2016-10-26 | 辉瑞公司 | 吡咯并[2,3‑d]嘧啶基、吡咯并[2,3‑b]吡嗪基和吡咯并[2,3‑d]吡啶基丙烯酰胺 |
CN108069986A (zh) * | 2017-12-08 | 2018-05-25 | 牡丹江医学院 | 一种治疗角膜炎的活性药物及其制备方法 |
CN109689663A (zh) * | 2016-09-14 | 2019-04-26 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR101214A1 (es) * | 2014-07-22 | 2016-11-30 | Bayer Cropscience Ag | Ciano-cicloalquilpenta-2,4-dienos, ciano-cicloalquilpent-2-en-4-inas, ciano-heterociclilpenta-2,4-dienos y ciano-heterociclilpent-2-en-4-inas sustituidos como principios activos contra el estrés abiótico de plantas |
CN110291090A (zh) * | 2017-01-20 | 2019-09-27 | 利奥制药有限公司 | 作为新型jak激酶抑制剂的双环胺 |
US10799507B2 (en) * | 2017-02-03 | 2020-10-13 | Leo Pharma A/S | 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors |
WO2020092015A1 (fr) | 2018-11-02 | 2020-05-07 | University Of Rochester | Atténuation thérapeutique d'une infection épithéliale |
CN114599364A (zh) | 2019-09-05 | 2022-06-07 | 因赛特公司 | 用于减少特应性皮炎瘙痒的鲁索替尼制剂 |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065908A1 (fr) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | COMPOSES DE PYRROLO[2,3d]PYRIMIDINE |
CN1305479A (zh) * | 1998-06-19 | 2001-07-25 | 辉瑞产品公司 | 吡咯并[2,3-d]嘧啶化合物 |
WO2009021169A2 (fr) * | 2007-08-08 | 2009-02-12 | Lexicon Pharmaceuticals, Inc. | Inhibiteurs de kinase, compositions les contenant et procédés d'utilisation |
CN101679440A (zh) * | 2007-04-02 | 2010-03-24 | 帕劳制药股份有限公司 | 作为jak3抑制剂的吡咯并嘧啶衍生物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
ATE477252T1 (de) | 2006-07-14 | 2010-08-15 | Merck Sharp & Dohme | Substituierte diazepane als antagonisten an orexinrezeptoren |
WO2009017838A2 (fr) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
EA017952B1 (ru) | 2008-02-06 | 2013-04-30 | Новартис Аг | ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ |
WO2009131687A2 (fr) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibiteurs de protéines kinases |
-
2011
- 2011-07-08 CN CN2011800339890A patent/CN102985425A/zh active Pending
- 2011-07-08 RU RU2013105450/04A patent/RU2013105450A/ru not_active Application Discontinuation
- 2011-07-08 JP JP2013517018A patent/JP2013533868A/ja active Pending
- 2011-07-08 TW TW100124316A patent/TW201204732A/zh unknown
- 2011-07-08 WO PCT/DK2011/000080 patent/WO2012003829A1/fr active Application Filing
- 2011-07-08 US US13/809,059 patent/US9586961B2/en not_active Expired - Fee Related
- 2011-07-08 EP EP11738151.7A patent/EP2590981B1/fr not_active Not-in-force
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999065908A1 (fr) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | COMPOSES DE PYRROLO[2,3d]PYRIMIDINE |
CN1305479A (zh) * | 1998-06-19 | 2001-07-25 | 辉瑞产品公司 | 吡咯并[2,3-d]嘧啶化合物 |
CN101679440A (zh) * | 2007-04-02 | 2010-03-24 | 帕劳制药股份有限公司 | 作为jak3抑制剂的吡咯并嘧啶衍生物 |
WO2009021169A2 (fr) * | 2007-08-08 | 2009-02-12 | Lexicon Pharmaceuticals, Inc. | Inhibiteurs de kinase, compositions les contenant et procédés d'utilisation |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104072499A (zh) * | 2013-03-29 | 2014-10-01 | 黄传满 | 哌嗪取代嘧啶类化合物及其用途 |
CN103242321A (zh) * | 2013-05-21 | 2013-08-14 | 苏州科捷生物医药有限公司 | 苄基哌嗪类化合物及其抗肿瘤用途 |
CN103396414A (zh) * | 2013-07-16 | 2013-11-20 | 浙江医药高等专科学校 | 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
CN103396414B (zh) * | 2013-07-16 | 2015-06-03 | 浙江医药高等专科学校 | 咪唑取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
CN106061973A (zh) * | 2013-12-05 | 2016-10-26 | 辉瑞公司 | 吡咯并[2,3‑d]嘧啶基、吡咯并[2,3‑b]吡嗪基和吡咯并[2,3‑d]吡啶基丙烯酰胺 |
CN107417684A (zh) * | 2013-12-05 | 2017-12-01 | 辉瑞公司 | 杂环丙烯酰胺 |
CN106061973B (zh) * | 2013-12-05 | 2019-07-09 | 辉瑞公司 | 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺 |
CN105712998A (zh) * | 2014-12-05 | 2016-06-29 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
CN105712998B (zh) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
CN109689663A (zh) * | 2016-09-14 | 2019-04-26 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
CN109689663B (zh) * | 2016-09-14 | 2023-04-14 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
CN108069986A (zh) * | 2017-12-08 | 2018-05-25 | 牡丹江医学院 | 一种治疗角膜炎的活性药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2013533868A (ja) | 2013-08-29 |
EP2590981A1 (fr) | 2013-05-15 |
EP2590981B1 (fr) | 2014-09-03 |
TW201204732A (en) | 2012-02-01 |
RU2013105450A (ru) | 2014-08-20 |
US9586961B2 (en) | 2017-03-07 |
WO2012003829A1 (fr) | 2012-01-12 |
US20130172325A1 (en) | 2013-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102985425A (zh) | 作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途 | |
CN102574857B (zh) | 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物 | |
AU2016240033B2 (en) | 1-cyano-pyrrolidine compounds as USP30 inhibitors | |
EP3324977B1 (fr) | Dérivés benzodiazépine utilisés comme inhibiteurs du virus respiratoire syncytial (rsv) | |
CA2588761C (fr) | Derives de 2,4(4,6)pyrimidine | |
CN1871240B (zh) | 吡咯并嘧啶酮衍生物 | |
KR101828187B1 (ko) | 신규 축합 피리미딘 화합물 또는 그 염 | |
CN104884458A (zh) | 作为蛋白质激酶抑制剂的稠合杂环化合物 | |
KR101171433B1 (ko) | 이미다졸리딘온 유도체 | |
CN112312904A (zh) | 螺环化合物 | |
WO2014113191A1 (fr) | Inhibiteurs de la voie signalisation hedgehog et leurs applications thérapeutiques | |
NZ539193A (en) | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same | |
WO2008072779A1 (fr) | Dérivé de quinoxaline | |
EP3336084A1 (fr) | Dérivés de 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamide et leur utilisation en tant qu'inhibiteurs de phd | |
HUE034807T2 (en) | New quinoline-substituted compound | |
AU2018351059B2 (en) | Benzimidazole derivatives and their uses | |
CN102596962A (zh) | Jak抑制剂 | |
CN111386275B (zh) | 高活性sting蛋白激动剂 | |
WO2020210379A1 (fr) | Inhibiteur de la phosphatidylinositol 3-kinase | |
KR20110084556A (ko) | 신경발생을 자극 및 신경 퇴화를 억제하는 방법 및 조성물 | |
KR20200090636A (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
CN111032630A (zh) | 一种化合物,其药物组合物及其用途及应用 | |
CN111315734A (zh) | 作为食欲素受体拮抗剂的经取代的2-氮杂双环[3.1.1]庚烷和2-氮杂双环[3.2.1]辛烷衍生物 | |
WO2020150545A1 (fr) | DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE | |
JP2021512942A (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびmGlu5受容体のモジュレータとしてのそれらの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1181752 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130320 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1181752 Country of ref document: HK |